Personal information

Other IDs

Scopus Author ID: 7003388618

Countries

Ukraine

Activities

Collapse all

Employment (1)

National Pirogov Memorial Medical University, Vinnytsya: Vinnytsia, UA

2001 to present | Head of Department (Department of Endocrinology)
Employment
Source: Self-asserted source
Maryna Vlasenko

Education and qualifications (2)

National Pirogov Memorial Medical University, Vinnytsya: Vinnytsia, UA

1987 to 1990 | PhD (graduate school in endocrinology)
Education
Source: Self-asserted source
Maryna Vlasenko

National Pirogov Memorial Medical University, Vinnytsya: Vinnytsia, UA

1978 to 1984 | MD (medicine)
Education
Source: Self-asserted source
Maryna Vlasenko

Works (11)

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine
2019-01-24 | Journal article
DOI: 10.1056/nejmoa1812389
Part of ISSN: 0028-4793
Part of ISSN: 1533-4406
Source: Self-asserted source
Maryna Vlasenko

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

The Lancet
2018-10 | Journal article
DOI: 10.1016/s0140-6736(18)32261-x
Part of ISSN: 0140-6736
Source: Self-asserted source
Maryna Vlasenko

Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes

Diabetes, Obesity and Metabolism
2015-01 | Journal article
DOI: 10.1111/dom.12393
Part of ISSN: 1462-8902
Source: Self-asserted source
Maryna Vlasenko

Impact of hypoglycemia on daily life of type 2 diabetes patients in Ukraine

Journal of Multidisciplinary Healthcare
2013 | Journal article
DOI: 10.2147/JMDH.S39133
EID:

2-s2.0-84880233365
Contributors: Mandrik, O.; Severens, J.L.; Doroshenko, O.; Pan'kiv, V.; Kravchun, N.; Vlasenko, M.; Hulchiy, M.; Baljuk, M.; Komisarenko, Y.; Martsynik, E. et al.
Source: Self-asserted source
Maryna Vlasenko via Scopus - Elsevier

Hypothalamic syndrome

2012 | Other
URI:

http://cyberleninka.ru/article/n/hypothalamic-syndrome
Source: Self-asserted source
Maryna Vlasenko

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

The Lancet
2011-08 | Journal article
DOI: 10.1016/s0140-6736(11)60931-8
Part of ISSN: 0140-6736
Source: Self-asserted source
Maryna Vlasenko

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

Diabetes, Obesity and Metabolism
2011-03 | Journal article
DOI: 10.1111/j.1463-1326.2010.01350.x
Part of ISSN: 1462-8902
Source: Self-asserted source
Maryna Vlasenko

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

Diabetic Medicine
2010-09 | Journal article
DOI: 10.1111/j.1464-5491.2010.03020.x
Part of ISSN: 0742-3071
Source: Self-asserted source
Maryna Vlasenko

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial

Diabetes, Obesity and Metabolism
2009 | Journal article
DOI: 10.1111/j.1463-1326.2009.01056.x
EID:

2-s2.0-65549123794
Contributors: Jadzinsky, M.; Pfützner, A.; Paz-Pacheco, E.; Xu, Z.; Allen, E.; Chen, R.; Antunez, P.; Baccaro, C.; Bertone, R.; Bragagnolo, J. et al.
Source: Self-asserted source
Maryna Vlasenko via Scopus - Elsevier

Lipid peroxidation in patients with chronic adrenocortical insufficiency

Problemy Endokrinologii
1990 | Journal article
EID:

2-s2.0-0025064229
Contributors: Zelinsky, B.A.; Vlasenko, M.V.
Source: Self-asserted source
Maryna Vlasenko via Scopus - Elsevier

Fat metabolism in hypocorticism patients,Zhirovoǐ obmen u bol'nykh s gipokortitsizmom.

Vrachebnoe delo
1989 | Journal article
EID:

2-s2.0-0024677426
Contributors: Vlasenko, M.V.
Source: Self-asserted source
Maryna Vlasenko via Scopus - Elsevier
How many people are using ORCID?